These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21870818)

  • 41. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
    Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
    Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.
    Haddach M; Pierre F; Regan CF; Borsan C; Michaux J; Stefan E; Kerdoncuff P; Schwaebe MK; Chua PC; Siddiqui-Jain A; Macalino D; Drygin D; O'Brien SE; Rice WG; Ryckman DM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):45-8. PubMed ID: 22169261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Features and potentials of ATP-site directed CK2 inhibitors.
    Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
    Liu S; Hsieh D; Yang YL; Xu Z; Peto C; Jablons DM; You L
    BMC Pharmacol Toxicol; 2013 Jul; 14():36. PubMed ID: 23845105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.
    Bestgen B; Kufareva I; Seetoh W; Abell C; Hartmann RW; Abagyan R; Le Borgne M; Filhol O; Cochet C; Lomberget T; Engel M
    J Med Chem; 2019 Feb; 62(4):1817-1836. PubMed ID: 30689946
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
    Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a novel function of CX-4945 as a splicing regulator.
    Kim H; Choi K; Kang H; Lee SY; Chi SW; Lee MS; Song J; Im D; Choi Y; Cho S
    PLoS One; 2014; 9(4):e94978. PubMed ID: 24743259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expanding the chemical diversity of CK2 inhibitors.
    Prudent R; Moucadel V; López-Ramos M; Aci S; Laudet B; Mouawad L; Barette C; Einhorn J; Einhorn C; Denis JN; Bisson G; Schmidt F; Roy S; Lafanechere L; Florent JC; Cochet C
    Mol Cell Biochem; 2008 Sep; 316(1-2):71-85. PubMed ID: 18563535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.
    Girardi C; Ottaviani D; Pinna LA; Ruzzene M
    Biomed Res Int; 2015; 2015():185736. PubMed ID: 26558259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.
    Cozza G; Venerando A; Sarno S; Pinna LA
    Biomed Res Int; 2015; 2015():734127. PubMed ID: 26558278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein kinase CK2 inhibition as a pharmacological strategy.
    Borgo C; Ruzzene M
    Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
    Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
    Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The protein kinase CK2 catalytic domain from Plasmodium falciparum: crystal structure, tyrosine kinase activity and inhibition.
    Ruiz-Carrillo D; Lin J; El Sahili A; Wei M; Sze SK; Cheung PCF; Doerig C; Lescar J
    Sci Rep; 2018 May; 8(1):7365. PubMed ID: 29743645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
    Rabalski AJ; Gyenis L; Litchfield DW
    Clin Cancer Res; 2016 Jun; 22(12):2840-7. PubMed ID: 27306791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.